Qinxian Tu, Yizhuo Duan, Xiongjing Jiang, Hui Dong, Yubao Zou
{"title":"Clinical and Biochemical Outcomes of Super-Selective Adrenal Artery Embolization in Primary Aldosteronism: A Systematic Review and Meta-Analysis","authors":"Qinxian Tu, Yizhuo Duan, Xiongjing Jiang, Hui Dong, Yubao Zou","doi":"10.1111/jch.70088","DOIUrl":null,"url":null,"abstract":"<p>This systematic review and meta-analysis study evaluated the clinical and biochemical efficacy of super-selective adrenal artery embolization (SAAE) in patients with primary aldosteronism (PA). The primary outcome was the change in office blood pressure, while secondary outcomes included changes in plasma aldosterone and serum potassium levels following the procedure. A systematic search of Embase, PubMed, Ovid, Web of Science, China National Knowledge Infrastructure, Wanfang, and SinoMed was conducted through December 14, 2024. Seventeen studies involving 650 patients (aged 28–65 years) with a median follow-up of 6 months were included. Meta-analysis, subgroup analysis, publication bias assessment, and sensitivity analysis were performed using RevMan 5.3 and R 4.2.3. The results showed that SAAE significantly reduced systolic (MD = −19.84 mmHg, 95% CI: −22.87 to −16.82 mmHg) and diastolic blood pressure (MD = −10.62 mmHg, 95% CI: −12.61 to −8.64 mmHg), lowered plasma aldosterone levels (MD = −90.99 pg/mL, 95% CI: −119.36 to −62.63 pg/mL), and increased serum potassium levels (MD = 0.59 mmol/L, 95% CI: 0.49–0.70 mmol/L). Subgroup analyses confirmed benefits in patients with both idiopathic hyperaldosteronism and aldosterone-producing adenoma. These findings support SAAE as an effective treatment for improving clinical outcomes and correcting biochemical abnormalities in PA.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"27 7","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jch.70088","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Hypertension","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jch.70088","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
This systematic review and meta-analysis study evaluated the clinical and biochemical efficacy of super-selective adrenal artery embolization (SAAE) in patients with primary aldosteronism (PA). The primary outcome was the change in office blood pressure, while secondary outcomes included changes in plasma aldosterone and serum potassium levels following the procedure. A systematic search of Embase, PubMed, Ovid, Web of Science, China National Knowledge Infrastructure, Wanfang, and SinoMed was conducted through December 14, 2024. Seventeen studies involving 650 patients (aged 28–65 years) with a median follow-up of 6 months were included. Meta-analysis, subgroup analysis, publication bias assessment, and sensitivity analysis were performed using RevMan 5.3 and R 4.2.3. The results showed that SAAE significantly reduced systolic (MD = −19.84 mmHg, 95% CI: −22.87 to −16.82 mmHg) and diastolic blood pressure (MD = −10.62 mmHg, 95% CI: −12.61 to −8.64 mmHg), lowered plasma aldosterone levels (MD = −90.99 pg/mL, 95% CI: −119.36 to −62.63 pg/mL), and increased serum potassium levels (MD = 0.59 mmol/L, 95% CI: 0.49–0.70 mmol/L). Subgroup analyses confirmed benefits in patients with both idiopathic hyperaldosteronism and aldosterone-producing adenoma. These findings support SAAE as an effective treatment for improving clinical outcomes and correcting biochemical abnormalities in PA.
期刊介绍:
The Journal of Clinical Hypertension is a peer-reviewed, monthly publication that serves internists, cardiologists, nephrologists, endocrinologists, hypertension specialists, primary care practitioners, pharmacists and all professionals interested in hypertension by providing objective, up-to-date information and practical recommendations on the full range of clinical aspects of hypertension. Commentaries and columns by experts in the field provide further insights into our original research articles as well as on major articles published elsewhere. Major guidelines for the management of hypertension are also an important feature of the Journal. Through its partnership with the World Hypertension League, JCH will include a new focus on hypertension and public health, including major policy issues, that features research and reviews related to disease characteristics and management at the population level.